metadata toggle
Dosage and administration
Dosage schedule
The recommended minimum doses for cats are 10 mg/kg body weight imidacloprid and 1.0 mg/kg body weight moxidectin, equivalent to 0.1ml/kg body weight Advocate for cats.
Dosage schedule for ferrets: one pipette of Advocate spot-on solution for small cats and ferrets (0.4 ml) should be administered per animal. Do not exceed the recommended dose.
The recommended minimum doses for dogs are 10 mg/kg body weight imidacloprid and 2.5 mg/kg body weight moxidectin, equivalent to 0.1ml/kg body weight Advocate for dogs.
The treatment schedule for all species should be based on individual veterinary diagnosis and on the local epidemiological situation.
Cats (Refer to Table 1)
Table 1:
Weight of CAT [kg]
Pipette size to be used
Volume (ml)
Imidacloprid [mg/kg bw]
Moxidectin [mg/kg bw]
≤4kg
Advocate for small cats and ferrets
0.4
minimum of 10
minimum of 1
>4-8kg
Advocate for large cats
0.8
10-20
1-2
>8kg
the appropriate combination of pipettes
Dogs(Refer to Table 2)
Table 2:
Weight of DOG [kg]
Pipette size to be used
Volume (ml)
Imidacloprid [mg/kg bw]
Moxidectin [mg/kg bw]
≤4kg
Advocate for small dogs
0.4
minimum of 10
minimum of 2.5
>4-10kg
Advocate for medium dogs
1.0
10-25
2.5-6.25
>10-25kg
Advocate for large dogs
2.5
10-25
2.5-6.25
>25-40kg
Advocate for extra-large dogs
4.0
10-16
2.5-4
>40kg
the appropriate combination of pipettes
Flea treatment and prevention (Ctenocephalides felis) (Cats & Dogs)
One treatment prevents future flea infestation for 4 weeks. Existing pupae in the environment may emerge for 6 weeks or longer after treatment is initiated, depending upon climatic conditions. Therefore, it may be necessary to combine Advocate treatment with environmental treatments aimed at breaking the flea life cycle in the surroundings. This can result in a more rapid reduction in the household flea population. The product should be administered at monthly intervals when used as part of a treatment strategy for flea allergy dermatitis.
Flea treatment and prevention (Ctenocephalides felis) (Ferrets)
One treatment prevents future flea infestation for 3 weeks. Under heavy flea pressure it may be necessary to repeat the dose after 2 weeks.
Treatment of ear mite infestation (Otodectes cynotis) (Cats & Dogs)
A single dose of the product should be administered. In dogs, loose debris should be gently removed from the external ear canal at each treatment. For both cats and dogs, a further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
Treatment of biting lice (Trichodectes canis) (Dogs)
A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
Treatment of sarcoptic mange (caused by Sarcoptes scabiei var. canis) (Dogs)
A single dose should be administered twice 4 weeks apart.
Treatment of notoedric mange (Notoedres cati) (Cats)
A single dose of the product should be administered.
Treatment of the lungworm Eucoleus aerophilus (syn. Capillaria aerophila) (adults) (Cats)
A single dose of the product should be administered.
Prevention of Aelurostrongylus abstrusus (Cats)
The product should be administered monthly.
Treatment of Aelurostrongylus abstrusus (Cats)
Advocate should be administered monthly for three consecutive months.
Treatment of Eucoleus (syn. Capillaria) boehmi (adults) (Dogs)
The product should be administered monthly for two consecutive months. It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection.
Treatment of the eye worm Thelazia callipaeda (adults) (Cats & Dogs)
A single dose of the product should be administered.
Treatment of demodicosis (caused by Demodex canis) (Dogs)
The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, Advocate can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian.
As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
Prevention of heartworm disease (D.immitis) (Cats, Ferrets & Dogs)
Cats, ferrets and dogs in areas endemic for heartworm, or those which have travelled to endemic areas, may be infected with adult heartworms. Therefore prior to treatment with Advocate, the advice provided in Contra-Indications and Warnings etc should be considered. For prevention of heartworm disease, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. immitis larvae) are present. The product may be administered throughout the year. The first dose may be given after first possible exposure to mosquitoes, but not more than one month after this exposure. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month. When replacing another heartworm preventative product in a heartworm prevention programme, the first treatment with Advocate must be given within 1 month of the last dose of the former medication. In non-endemic areas there should be no risk of animals having heartworm. Therefore, they can be treated without special precautions.
Prevention of cutaneous dirofilariosis (skinworm) (D. repens) (Dogs)
For prevention of cutaneous dirofilariosis, the product must be applied at regular monthly intervals during the time of the year when mosquitoes (the intermediate hosts which carry and transmit D. repens larvae) are present. The product may be administered throughout the year or at least 1 month before the first expected exposure to mosquitoes. Treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes. To establish a treatment routine, it is recommended that the same day or date be used each month.
Treatment of microfilariae (D. immitis) (Dogs)
Advocate should be administered monthly for two consecutive months.
Treatment of cutaneous dirofilariosis (skin worm) (adult stages of Dirofilaria repens) (Dogs)
Advocate should be administered monthly for six consecutive months.
Reduction of microfilariae (skin worm) (D. repens) (Dogs)
The product should be administered monthly for four consecutive months.
Roundworm and hookworm treatment (Toxocara cati and Ancylostoma tubaeforme)(Cats)
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective roundworms and hookworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes.
Roundworm, hookworm and whipworm treatment (Toxocara canis, Ancylostoma caninum, Uncinaria stenocephala, Toxascaris leonina and Trichuris vulpis) (Dogs)
In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes. Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.
Treatment and Prevention of Angiostrongylus vasorum (Dogs)
A single dose should be administered. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.
In endemic areas regular four weekly application will prevent angiostrongylosis and patent infection with Angiostrongylus vasorum.
Treatment of Crenosoma vulpis (Dogs)
A single dose should be administered
Prevention of spirocercosis Spirocerca lupi (Dogs)
The product should be administered monthly.
Method of administration
For external use only.
Remove one pipette from the package. Then hold the pipette in an upright position, and twist and pull off the cap. Reverse the cap and use it to twist and remove the seal from the pipette, as shown. See Figure 1.
Description: h-298
Figure 1: Opening a pipette
Cats and Ferrets
Part the fur on the animal's neck at the base of the skull until the skin is visible. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. Application at the base of the skull will minimise the opportunity for the animal to lick the product. Apply only to undamaged skin. See Figure 2.
Description: h-530
Figure 2: Administration to the Cat or Ferret
For dogs up to 25kg
With the dog in a standing position, part the coat between the shoulder blades until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and squeeze the pipette firmly several times to empty its contents directly onto the skin. See Figure 3.
Description: h-301
Figure 3: Administration to dogs up to 25kg
For dogs of more than 25 kg
For easy application the dog should be standing. The entire contents of the pipette should be applied evenly as 3 or 4 spots along the top of the back, from between the shoulders to the base of the tail. At each spot, part the coat until the skin is visible. Wherever possible apply to undamaged skin. Place the tip of the pipette on the skin and gently squeeze the pipette to expel a portion of its contents directly onto the skin. Do not apply an excessive amount of solution at any one spot, as that could cause some of the product to run down the animal’s side. See Figure 4.
Description: h-302
Figure 4: Administration to dogs over 25kg
Use During Pregnancy and Lactation
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Laboratory studies with either imidacloprid or moxidectin in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use only according to the risk-benefit assessment by the responsible veterinarian.